A consideration of PPAR-gamma ligands with respect to lipophilicity: current trends and perspectives (Q36763993)

16 August 2017

title

A consideration of PPAR-gamma ligands with respect to lipophilicity: current trends and perspectives (English)

1 reference

16 August 2017

2

Stamatios Theocharis

1 reference

16 August 2017

Costas Giaginis

1

1 reference

16 August 2017

Anna Tsantili-Kakoulidou

series ordinal

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Expert Opinion on Investigational Drugs

16 August 2017

published in

1 reference

16 August 2017

volume

16

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

413-417

1 reference

Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

The PPARs: from orphan receptors to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

PPARs and other nuclear receptors in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

Peroxisome proliferator-activated receptor gamma and metabolic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

Interaction between peroxisome proliferator-activated receptor gamma and its agonists: docking study of oximes having 5-benzyl-2,4-thiazolidinedione

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

Investigation of the retention/pH profile of zwitterionic fluoroquinolones in reversed-phase and ion-interaction high performance liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

3D QSAR studies on peroxisome proliferator-activated receptor gamma agonists using CoMFA and CoMSIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

Pharmacophore identification and 3D-QSAR studies in N-(2-benzoyl phenyl)-L-tyrosines as PPAR gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

Property distribution of drug-related chemical databases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

Lipophilicity Profiles of Ampholytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

PPAR Tissue Distribution and Interactions with Other Hormone-Signaling Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.4.413

10.1517/13543784.16.4.413

21 January 2018

Identifiers

DOI

1 reference

release_kbzxldgfdrf6hkv7uixio5z2fe

16 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kbzxldgfdrf6hkv7uixio5z2fe

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference